GLPwatch
Most-cited research
GLP-1 papers ranked by citation count.
- 1 Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- 2 Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- 3 Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- 4 Tirzepatide Once Weekly for the Treatment of Obesity.
- 5 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- 6 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- 7 A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- 8 Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- 9 Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- 10 Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- 11 EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
- 12 A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- 13 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- 14 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- 15 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- 16 Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
- 17 Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- 18 GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
- 19 Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
- 20 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
- 21 Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- 22 Liraglutide and Renal Outcomes in Type 2 Diabetes.
- 23 Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- 24 Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- 25 Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
- 26 Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- 27 Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- 28 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- 29 Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- 30 The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- 31 Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
- 32 Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
- 33 GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
- 34 Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- 35 An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
- 36 Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- 37 LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
- 38 Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- 39 The Discovery and Development of Liraglutide and Semaglutide.
- 40 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- 41 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- 42 Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
- 43 Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- 44 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- 45 Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- 46 Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- 47 Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
- 48 Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
- 49 Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
- 50 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- 51 The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
- 52 Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
- 53 Semaglutide lowers body weight in rodents via distributed neural pathways.
- 54 Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
- 55 Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- 56 EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
- 57 Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- 58 Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
- 59 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- 60 Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
- 61 Obesity Management in Adults: A Review.
- 62 Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- 63 Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
- 64 A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
- 65 Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
- 66 GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
- 67 Once-Weekly Semaglutide in Adolescents with Obesity.
- 68 Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
- 69 Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
- 70 Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- 71 Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
- 72 Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- 73 Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- 74 Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
- 75 Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
- 76 Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
- 77 Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- 78 Exenatide and the treatment of patients with Parkinson's disease.
- 79 Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
- 80 Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- 81 Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
- 82 Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
- 83 Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- 84 Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
- 85 Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
- 86 Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
- 87 GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
- 88 GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.
- 89 Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
- 90 The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- 91 Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
- 92 Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
- 93 Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
- 94 Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- 95 Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
- 96 Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
- 97 PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
- 98 Management of type 2 diabetes: new and future developments in treatment.
- 99 Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
- 100 Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.